Amneal Pharmaceuticals financials
$20.20−1.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $796.2M | $722.5M | $814.3M | $784.5M | $724.5M | $695.4M | $730.5M | $702.5M | $701.8M | $659.2M | $617.0M | $620.0M |
| Gross profit | $334.5M | $320.1M | $297.2M | $274.0M | $286.3M | $255.9M | $262.9M | $269.6M | $249.9M | $238.1M | $189.8M | $232.5M |
| Gross margin | 42.0% | 44.3% | 36.5% | 34.9% | 39.5% | 36.8% | 36.0% | 38.4% | 35.6% | 36.1% | 30.8% | 37.5% |
| Operating income | $129.8M | $141.8M | $106.8M | $70.3M | $111.4M | $100.3M | $74.9M | $88.8M | $95.5M | -$10.7M | $15.0M | $78.8M |
| Net income | $57.7M | $62.3M | $35.1M | $2.4M | $22.4M | $12.2M | -$31.1M | -$156.0K | $6.0M | -$91.6M | -$98.6M | $9.7M |
| Net margin | 7.2% | 8.6% | 4.3% | 0.3% | 3.1% | 1.8% | −4.3% | 0.0% | 0.9% | −13.9% | −16.0% | 1.6% |
| Diluted EPS | $0.18 | $0.19 | $0.11 | $0.01 | $0.07 | $0.04 | $-0.10 | $0.00 | $0.02 | $-0.30 | $-0.41 | $0.06 |
| EBITDA | $193.8M | $191.5M | $158.5M | $124.6M | $172.1M | $161.1M | $143.3M | $147.8M | $152.0M | $140.6M | $48.8M | $134.4M |
| Operating cash flow | -$21.2M | -$26.7M | $130.3M | $118.5M | $83.8M | $7.4M | $118.1M | $141.8M | $39.7M | -$4.4M | $135.8M | $77.5M |
| Free cash flow | -$51.9M | -$34.9M | $108.5M | $110.8M | $61.0M | -$5.8M | $102.9M | $125.8M | $29.0M | -$14.5M | $124.0M | $65.0M |
| Diluted shares | 328.1M | 328.9M | 328.1M | 324.8M | 322.4M | 324.0M | 300.0M | 309.6M | 319.0M | 307.3M | 237.9M | 159.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $127.6M | $197.7M | $282.0M | $201.2M | $71.5M | $59.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $2.67B | $2.63B | $2.57B | $2.57B | $2.53B | $2.54B |
| Total assets | $3.78B | $3.54B | $3.68B | $3.60B | $3.42B | $3.37B |
| Total liabilities | $3.66B | $3.50B | $3.67B | $3.64B | $3.47B | $3.42B |
| Shareholders' equity | $117.0M | -$46.0M | $6.0M | -$110.0M | -$112.5M | -$132.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology